Pharmaceutical manufacturer: IPO of Stada seam: “Interest from investors big”

The pharmaceutical manufacturer Stada earns more and drives his planned billion -dollar IPO. “We are talking to investors from the United States, Great Britain, Europe and the Middle East,” said Stada boss Peter Goldschmidt of the German Press Agency. “The interest is great, the feedback is positive.”

Previously, it became known that Stada was targeting an IPO in Frankfurt before Easter. The group, known for the GRIPPOSTAD cold, the sun milk Ladival and the Silomat cough juice could be rated at ten to twelve billion euros. This would probably make Stada one of the largest IPOs in Europe this year and a candidate for the MDAX or even DAX.

It is not known how many shares the owners, the financial investors Bain Capital and Cinven could submit on a IPO in April. They had bought Stada with around 11,600 employees in 2017 for 5.3 billion euros and later took it off the stock exchange. “Even in the event of an IPO, the financial investors want to remain invested and do not immediately sell their shares completely,” said Goldschmidt.

No decision has been made to a IPO yet. “We have to see what the stock market environment is. The geopolitical situation should not be underestimated at the moment.”

Bears of the stock market are rare in Germany, where in 2024 only a few companies dared to go to the floor, including the Douglas perfume chain. In addition to a IPO, the Stada owners had previously considered a sale, but the corresponding conversations were tough.

Profit 2024 grown significantly

Last year, Stada benefited from growing shops. Sales rose by 9 percent to a good four billion euros and the operating result (EBITDA) adjusted by special and currency effects by 11 percent to 886 million euros. There was no information on the net profit.

Goldschmidt said that they have grown more in Europe with over -the -counter medicines, as well as in the case of imitators and special medication in Europe. “In the home market in Germany we have experienced a good year with medication for over -the -counter, but we have not given a top demand for colds.”

Tackled again after the IPO again conceivable

Stada had grown in recent years – also thanks to a series of takeover that raised the debts. The Russian business, on the other hand, was split off because it was considered a burden on the sales plans. Now the debts of Stada should decrease during a IPO.

“In particular, we want to further strengthen our rapidly growing division with special medication with inventing,” said Goldschmidt. “If debts are reduced with the IPO, larger takeovers are also conceivable.”